Furthermore, our results demonstrate that GUT-70 can synergise the cytotoxic effects of the proteasome inhibitor bortezomib and the widely used genotoxic chemotherapeutic agent doxorubicin in MCL cells (Brody and Advani, 2006; Goy et al, 2009), regardless of p53 status. Here, TP53 is linked to mantle cell lymphoma.